Evidence map›Paper›PMID 32091262›Full record

ArticleThe American journal of drug and alcohol abuse2020

Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.

Jennifer Miles, Jason Howell, Dave Sheridan, George Braucht, Amy Mericle

Abstract read
In one paragraph

Article in The American journal of drug and alcohol abuse, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jennifer MilesThe Heller School for Social Policy and Management, Brandeis University , Waltham, MA, USA.
Jason HowellNational Alliance for Recovery Residences , St. Paul, MN, USA.
Dave SheridanNational Alliance for Recovery Residences , St. Paul, MN, USA.
George BrauchtNational Alliance for Recovery Residences , St. Paul, MN, USA.
Amy MericlePublic Health Institute, Alcohol Research Group , Emeryville, CA, USA.

Funding

Recovery Housing for Alcohol and Drug Use Disorders: A National Study of Availability, Characteristics, and Factors Associated with Evidence-based PracticesR01AA027782 · NIAAA · PUBLIC HEALTH INSTITUTE · PI MERICLE, AMY ADALE · 2019 to 2022
$2.3M
NIAAA NIH HHS R01 AA027782
6 · The paper itself

Abstract

Full and partial opioid agonists and opioid antagonist medications play an important role in containing the opioid epidemic. However, these medications have not been used to their full extent. Recovery support services, such as recovery residences (RRs), also play a key role. RRs may increase an individual's recovery capital, facilitate social support for abstinence, and foster a sense of community among residents. These processes may be critical for individuals with opioid use disorder (OUD). In combination these two recovery pathways have the potential to enhance one another and improve outcomes among residents with OUD. Barriers to doing so have resulted in a limited supply of residences that can support residents using opioid agonist and antagonist medications. This perspective describes key interpersonal and structural barriers to medication use among individuals with an OUD seeking support from a recovery residence and discusses measures for reducing these barriers. These measures include workforce development to address stigma and attitudinal barriers and enhancing residence capability to ensure resident safety and reduce potential diversion. The perspective also highlights the need for additional research to facilitate the identification of best practices to improve outcomes among residents treated with medications living in recovery residences.

Indexed as

Residential TreatmentBuprenorphineHumansNaltrexoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid EpidemicOpioid-Related DisordersSocial StigmaSocial SupportBuprenorphineNaltrexoneNarcotic Antagonistsimplementationopioid agonist therapyopioid use disorderpolicyRecoveryrecovery residence

Identifiers

PMID32091262
PMCPMC7260098

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.